New hope for Hard-to-Treat prostate cancer? early trial launches

NCT ID NCT06609005

Recruiting now Disease control Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called INV-9956 in 84 men with advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants take INV-9956 along with two other medicines to manage side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INV-9956 (given with dexamethasone and fludrocortisone acetate)
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 84 participants, so the drug may not prove effective or may have unexpected side effects. It is not a cure and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Beijing GoBroad Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
He'nan Cancer Hospital
RECRUITING

Zhengzhou, He'Nan, 450000, China
Hoag Family Cancer Institute
RECRUITING

Newport Beach, California, 92663, United States

Contact Email: •••••@•••••
Honor Health
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact Email: •••••@•••••
Hu'nan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hu'Nan, 410006, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, Liaoning, 110801, China
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210008, China
Next Oncology - Houston
RECRUITING

Houston, Texas, 77054, United States
Shandong Cancer Hospital
RECRUITING

Ji'nan, Shandong, 250000, China
Summit Cancer Centers
RECRUITING

Spokane, Washington, 99208, United States
The First Affiliated Hospital of Fujian Medical University
RECRUITING

Fuzhou, Fujian, 350005, China
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITING

Wenzhou, Zhejiang, China
The First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310003, China
The First People's Hospital of Foshan
NOT_YET_RECRUITING

Foshan, Guangdong, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300202, China
UC Irvine Medical Center
RECRUITING

Orange, California, 92868, United States
UT Health
RECRUITING

San Antonio, Texas, 78229, United States
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Hubei, Wuhan, China
Zhejiang Provincial People's Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.